Cargando…

Secondary prevention after ischaemic stroke: the ASPIRE-S study

BACKGROUND: Survivors of ischaemic stroke (IS) are at high-risk for future vascular events. Comprehensive information on the adequacy of secondary prevention after IS is lacking despite the knowledge that appropriate secondary prevention improves long-term patient outcomes. ASPIRE-S (Action on Secon...

Descripción completa

Detalles Bibliográficos
Autores principales: Brewer, Linda, Mellon, Lisa, Hall, Patricia, Dolan, Eamon, Horgan, Frances, Shelley, Emer, Hickey, Anne, Williams, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619229/
https://www.ncbi.nlm.nih.gov/pubmed/26492943
http://dx.doi.org/10.1186/s12883-015-0466-2
_version_ 1782397054169907200
author Brewer, Linda
Mellon, Lisa
Hall, Patricia
Dolan, Eamon
Horgan, Frances
Shelley, Emer
Hickey, Anne
Williams, David
author_facet Brewer, Linda
Mellon, Lisa
Hall, Patricia
Dolan, Eamon
Horgan, Frances
Shelley, Emer
Hickey, Anne
Williams, David
author_sort Brewer, Linda
collection PubMed
description BACKGROUND: Survivors of ischaemic stroke (IS) are at high-risk for future vascular events. Comprehensive information on the adequacy of secondary prevention after IS is lacking despite the knowledge that appropriate secondary prevention improves long-term patient outcomes. ASPIRE-S (Action on Secondary Prevention Interventions and Rehabilitation in Stroke) aimed to prospectively assess secondary prevention in patients 6 months following IS. METHODS: Consenting patients admitted with IS to three Dublin hospitals were recruited over 1 year, from October 2011. At 6 months post IS a comprehensive assessment was completed, modelled on the EUROASPIRE protocol for evaluation of the adequacy of secondary prevention in post-discharge cardiac patients. This assessment included measurements of blood pressure, body mass index and fasting lipid and glucose profiles. Secondary preventive medications and smoking status were also documented. RESULTS: Three hundred two patients (58 % male) participated, of whom 256 (85 %) were followed-up at 6 months. Mean age was 69 years (range 22–95). At follow-up, 68 % of patients had a BMI >25 kg/m(2) and 16.4 % were still smoking. Almost two-thirds (63.4 %) had a blood pressure >140/90 and 23 % had low-density-lipoprotein >2.5 mmol/L. 28 % of diabetic patients had HbA1c ≥7 %. Ninety seven percent of patients were on anti-platelet and/or anticoagulant therapy. Of those with atrial fibrillation, 82 % were anti-coagulated (mean INR of 2.4). Ninety-five percent were on lipid-lowering therapy and three-quarters were on anti-hypertensive therapy. CONCLUSION: This prospective multi-centre survey of IS patients demonstrated a high prevalence of remaining modifiable risk factors at 6 months post stroke, despite the widespread prescription of secondary preventive medications. There is scope to improve preventive measures after IS (in particular blood pressure) by incorporating evidence-based guidelines into quality assurance cycles in stroke care.
format Online
Article
Text
id pubmed-4619229
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46192292015-10-26 Secondary prevention after ischaemic stroke: the ASPIRE-S study Brewer, Linda Mellon, Lisa Hall, Patricia Dolan, Eamon Horgan, Frances Shelley, Emer Hickey, Anne Williams, David BMC Neurol Research Article BACKGROUND: Survivors of ischaemic stroke (IS) are at high-risk for future vascular events. Comprehensive information on the adequacy of secondary prevention after IS is lacking despite the knowledge that appropriate secondary prevention improves long-term patient outcomes. ASPIRE-S (Action on Secondary Prevention Interventions and Rehabilitation in Stroke) aimed to prospectively assess secondary prevention in patients 6 months following IS. METHODS: Consenting patients admitted with IS to three Dublin hospitals were recruited over 1 year, from October 2011. At 6 months post IS a comprehensive assessment was completed, modelled on the EUROASPIRE protocol for evaluation of the adequacy of secondary prevention in post-discharge cardiac patients. This assessment included measurements of blood pressure, body mass index and fasting lipid and glucose profiles. Secondary preventive medications and smoking status were also documented. RESULTS: Three hundred two patients (58 % male) participated, of whom 256 (85 %) were followed-up at 6 months. Mean age was 69 years (range 22–95). At follow-up, 68 % of patients had a BMI >25 kg/m(2) and 16.4 % were still smoking. Almost two-thirds (63.4 %) had a blood pressure >140/90 and 23 % had low-density-lipoprotein >2.5 mmol/L. 28 % of diabetic patients had HbA1c ≥7 %. Ninety seven percent of patients were on anti-platelet and/or anticoagulant therapy. Of those with atrial fibrillation, 82 % were anti-coagulated (mean INR of 2.4). Ninety-five percent were on lipid-lowering therapy and three-quarters were on anti-hypertensive therapy. CONCLUSION: This prospective multi-centre survey of IS patients demonstrated a high prevalence of remaining modifiable risk factors at 6 months post stroke, despite the widespread prescription of secondary preventive medications. There is scope to improve preventive measures after IS (in particular blood pressure) by incorporating evidence-based guidelines into quality assurance cycles in stroke care. BioMed Central 2015-10-23 /pmc/articles/PMC4619229/ /pubmed/26492943 http://dx.doi.org/10.1186/s12883-015-0466-2 Text en © Brewer et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Brewer, Linda
Mellon, Lisa
Hall, Patricia
Dolan, Eamon
Horgan, Frances
Shelley, Emer
Hickey, Anne
Williams, David
Secondary prevention after ischaemic stroke: the ASPIRE-S study
title Secondary prevention after ischaemic stroke: the ASPIRE-S study
title_full Secondary prevention after ischaemic stroke: the ASPIRE-S study
title_fullStr Secondary prevention after ischaemic stroke: the ASPIRE-S study
title_full_unstemmed Secondary prevention after ischaemic stroke: the ASPIRE-S study
title_short Secondary prevention after ischaemic stroke: the ASPIRE-S study
title_sort secondary prevention after ischaemic stroke: the aspire-s study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619229/
https://www.ncbi.nlm.nih.gov/pubmed/26492943
http://dx.doi.org/10.1186/s12883-015-0466-2
work_keys_str_mv AT brewerlinda secondarypreventionafterischaemicstroketheaspiresstudy
AT mellonlisa secondarypreventionafterischaemicstroketheaspiresstudy
AT hallpatricia secondarypreventionafterischaemicstroketheaspiresstudy
AT dolaneamon secondarypreventionafterischaemicstroketheaspiresstudy
AT horganfrances secondarypreventionafterischaemicstroketheaspiresstudy
AT shelleyemer secondarypreventionafterischaemicstroketheaspiresstudy
AT hickeyanne secondarypreventionafterischaemicstroketheaspiresstudy
AT williamsdavid secondarypreventionafterischaemicstroketheaspiresstudy
AT secondarypreventionafterischaemicstroketheaspiresstudy